Jean Jacques Bienaime Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Jean Jacques Bienaime is Director of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 473,792 shares of BMRN, which is worth approximately $29.6 Million. The most recent transaction as insider was on Feb 28, 2023, when has been sold 167,532 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 474K

0% 3M change

12.08% 12M change

Total Value Held $29.6 Million

JEAN JACQUES BIENAIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 28 2023	BUY Grant, award, or other acquisition	-	167,532 Added 25.56%	487,856 Common Stock
Feb 13 2023	SELL Open market or private sale	$654,900 $109.15 p/Share	6,000 Reduced 1.84%	320,324 Common Stock
Feb 13 2023	BUY Exercise of conversion of derivative security	$406,860 $67.81 p/Share	6,000 Added 1.81%	326,324 Common Stock
Feb 10 2023	SELL Open market or private sale	$1,651,650 $110.11 p/Share	15,000 Reduced 4.47%	320,324 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	$1,017,150 $67.81 p/Share	15,000 Added 4.28%	335,324 Common Stock
Jan 17 2023	SELL Open market or private sale	$1,115,500 $111.55 p/Share	10,000 Reduced 3.03%	320,424 Common Stock
Jan 17 2023	BUY Exercise of conversion of derivative security	$678,100 $67.81 p/Share	10,000 Added 2.94%	330,424 Common Stock
Jan 13 2023	SELL Open market or private sale	$1,122,500 $112.25 p/Share	10,000 Reduced 3.03%	320,424 Common Stock
Jan 13 2023	BUY Exercise of conversion of derivative security	$678,100 $67.81 p/Share	10,000 Added 2.94%	330,424 Common Stock
Dec 13 2022	SELL Open market or private sale	$106,890 $106.89 p/Share	1,000 Reduced 0.31%	320,424 Common Stock
Dec 02 2022	SELL Open market or private sale	$156,000 $104.0 p/Share	1,500 Reduced 0.46%	321,424 Common Stock
Nov 02 2022	BUY Small Acquisition	$8,612 $86.12 p/Share	100 Added 0.03%	322,924 Common Stock
Oct 31 2022	SELL Open market or private sale	$129,825 $86.55 p/Share	1,500 Reduced 0.46%	322,824 Common Stock
Oct 14 2022	SELL Open market or private sale	$359,560 $89.89 p/Share	4,000 Reduced 1.22%	324,324 Common Stock
Aug 15 2022	SELL Open market or private sale	$285,630 $95.21 p/Share	3,000 Reduced 0.91%	328,324 Common Stock
Aug 12 2022	SELL Open market or private sale	$379,000 $94.75 p/Share	4,000 Reduced 1.19%	331,324 Common Stock
May 06 2022	SELL Open market or private sale	$1,620,000 $81.0 p/Share	20,000 Reduced 5.63%	335,324 Common Stock
May 06 2022	BUY Exercise of conversion of derivative security	$749,200 $37.46 p/Share	20,000 Added 5.33%	355,324 Common Stock
May 05 2022	SELL Open market or private sale	$841,400 $84.14 p/Share	10,000 Reduced 2.9%	335,324 Common Stock
May 05 2022	BUY Exercise of conversion of derivative security	$374,600 $37.46 p/Share	10,000 Added 2.81%	345,324 Common Stock
Apr 29 2022	SELL Open market or private sale	$409,750 $81.95 p/Share	5,000 Reduced 1.47%	334,983 Common Stock
Apr 29 2022	BUY Grant, award, or other acquisition	$21,282 $62.41 p/Share	341 Added 0.1%	335,324 Common Stock
Apr 29 2022	BUY Exercise of conversion of derivative security	$187,300 $37.46 p/Share	5,000 Added 1.45%	339,983 Common Stock
Apr 28 2022	SELL Open market or private sale	$1,675,800 $83.79 p/Share	20,000 Reduced 5.63%	334,983 Common Stock
Apr 28 2022	BUY Exercise of conversion of derivative security	$749,200 $37.46 p/Share	20,000 Added 5.33%	354,983 Common Stock

Also insider at

INCY

INCYTE CORP Healthcare

Director

IMNM

Immunome Inc. Healthcare

KROS

Keros Therapeutics, Inc. Healthcare

JJB